Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771877 | 1.00 | GAA (0.56) | GAAMAPTKDM4EPTK2BMAPK1 | |
| Hydrochloric Acid SCHEMBL3502999 | 0.99 | MAPT (0.55) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL1527170 | 0.88 | MAPT (0.53) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL24071969 | 0.87 | ALDH1A1 (0.49) | GAAMAPTKDM4EPTK2BMAPK1 | |
| Hydrochloric Acid SCHEMBL1527169 | 0.87 | MAPT (0.51) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL16003521 | 0.84 | SIRT6 (0.45) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL4181229 | 0.82 | CASP6 (0.54) | MAPTKMT2AGFERPDK2MEN1 | |
| SCHEMBL29566676 | 0.82 | SIRT6 (0.46) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL441957 | 0.82 | SIRT6 (0.44) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL24310611 | 0.82 | SIRT6 (0.46) | GAAMAPTKDM4EPTK2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| US-20240025887-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-01-25 | — | — | US | disclosed |
| US-20240025887-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-01-25 | — | — | US | disclosed |
| EP-4277902-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2023-11-22 | — | — | EP | disclosed |
| EP-4274829-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2023-11-15 | — | — | EP | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022147620-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022147620-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
| EP-2417125-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-15 | — | — | EP | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
| CN-102076689-A | Pyrazolo-quinazolines | NERVIANO MEDICAL SCIENCES SRL | 2011-05-25 | — | — | CN | disclosed |
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | US | disclosed |
| EP-2303891-A1 | PYRAZOLO-QUINAZOLINES | Nerviano Medical Sciences S.r.l. (IT) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009156315-A1 | PYRAZOLO-QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-12-30 | — | — | WO | disclosed |
| CN-101563351-A | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025887-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, PNKP | GAA 1593/4885MAPT 1981/4885KDM4E 1757/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | GAA 1092/4885MAPT 2799/4885KDM4E 1962/4885 |
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | PDXK, MAP4K5, MAP3K1 | GAA 679/4885MAPT 2518/4885KDM4E 3480/4885 |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | GAA 1449/4885MAPT 1573/4885KDM4E 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.